Through its Prevention beyond the pipeline Program,The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Duration:
- Multi-year
Average award:
- Up to $3,000,000 for clinical trials based on stage and scope of research . For studies requiring additional support, co-funding from other funding agencies or investors is encouraged
Deadline for LoI: 13th May 2024.